126 related articles for article (PubMed ID: 25025755)
1. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Guérin A; Chen L; Ionescu-Ittu R; Marynchenko M; Nitulescu R; Hiscock R; Keir C; Wu EQ
Curr Med Res Opin; 2014 Nov; 30(11):2317-28. PubMed ID: 25025755
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Cortes JE; Lipton JH; Miller CB; Busque L; Akard LP; Pinilla-Ibarz J; Keir C; Warsi G; Lin FP; Mauro MJ
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):286-96. PubMed ID: 26993758
[TBL] [Abstract][Full Text] [Related]
3. [To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):728-736. PubMed ID: 38049316
[No Abstract] [Full Text] [Related]
4. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J; Koh Y; Yoon SH; Cho JY; Kim DY; Lee KH; Kim HJ; Ahn JS; Kim YK; Park J; Sohn SK; Moon JH; Lee YJ; Yoon S; Lee JO; Cheong JW; Kim KH; Kim SH; Kim HG; Kim H; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Shin DY; Oh D; Kim MK; Jung CW; Park S; Kim I
Cancer Med; 2018 May; 7(5):1814-1823. PubMed ID: 29577674
[TBL] [Abstract][Full Text] [Related]
5. Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.
Kronick O; Chen X; Mehra N; Varmeziar A; Fisher R; Kartchner D; Kota V; Mitchell CS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686630
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.
Tobaiqy M; Helmi N; MacLure K; Saade S
Int J Clin Pharm; 2024 Apr; 46(2):368-381. PubMed ID: 38147280
[TBL] [Abstract][Full Text] [Related]
7. Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients.
Hamerschlak N; Souza Cd; Cornacchioni AL; Pasquini R; Tabak D; Spector N; Steagall M
Sao Paulo Med J; 2015; 133(6):471-9. PubMed ID: 25388686
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia.
Wan Puteh SE; Aizuddin AN; Tumian NR; Sathar J; Mohamad Selamat E
PLoS One; 2021; 16(8):e0256804. PubMed ID: 34449814
[TBL] [Abstract][Full Text] [Related]
9. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Akin G; İlhan O
Hematology; 2018 Feb; ():1-7. PubMed ID: 29486663
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
Hughes TP; Munhoz E; Aurelio Salvino M; Ong TC; Elhaddad A; Shortt J; Quach H; Pavlovsky C; Louw VJ; Shih LY; Turkina AG; Meillon L; Jin Y; Acharya S; Dalal D; Lipton JH
Br J Haematol; 2017 Oct; 179(2):219-228. PubMed ID: 28699641
[TBL] [Abstract][Full Text] [Related]
11. Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia and the occurrence of anxiety symptoms.
Gibek K; Sacha T; Cyranka K
Psychiatr Pol; 2024 Feb; 58(1):25-38. PubMed ID: 36542767
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
Chelysheva E; Apperley J; Turkina A; Yassin MA; Rea D; Nicolini FE; Barraco D; Kazakbaeva K; Saliev S; Abulafia AS; Al-Kindi S; Byrne J; Robertson HF; Cerrano M; Shmakov R; Polushkina E; de Fabritiis P; Trawinska MM; Abruzzese E
Leukemia; 2024 Apr; 38(4):788-795. PubMed ID: 38388649
[TBL] [Abstract][Full Text] [Related]
13. Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report.
Sachdeva M; Singh J; Dayal S; Gupta A
Indian Dermatol Online J; 2024; 15(3):492-495. PubMed ID: 38845649
[TBL] [Abstract][Full Text] [Related]
14. Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies.
Cottone F; Collins GS; Anota A; Sommer K; Giesinger JM; Kieffer JM; Aaronson NK; Van Steen K; Charton E; Castagnetti F; Fazi P; Vignetti M; Cella D; Efficace F
J Clin Epidemiol; 2020 Nov; 127():9-18. PubMed ID: 32562837
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Time to Onset and Outcome of Cardiac Adverse Events Associated with Nilotinib using Post-Marketing Surveillance.
Kanbayashi Y; Kojima A; Wakabayashi H; Shimizu T; Uchida M
Oncology; 2023; 101(12):799-807. PubMed ID: 37598671
[TBL] [Abstract][Full Text] [Related]
16. HRQoL in patients receiving EV versus chemotherapy.
Masone MC
Nat Rev Urol; 2024 May; 21(5):257. PubMed ID: 38627550
[No Abstract] [Full Text] [Related]
17. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A; Saglio G; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre PD; Etienne G; Dorlhiac-Llacer PE; Clark RE; Flinn IW; Nakamae H; Donohue B; Deng W; Dalal D; Menssen HD; Kantarjian HM
Leukemia; 2016 May; 30(5):1044-54. PubMed ID: 26837842
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura M
Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]